- Home
- TII vs PBYI Comparison
TII vs PBYI Comparison
Compare TII & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TII | PBYI |
|---|---|---|
| Founded | 2012 | 2010 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 231.0M | 263.4M |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | TII | PBYI |
|---|---|---|
| Price | $2.50 | $6.10 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $6.38 | N/A |
| AVG Volume (30 Days) | 328.3K | ★ 432.9K |
| Earning Date | 03-20-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.61 |
| Revenue | N/A | ★ $27,685,000.00 |
| Revenue This Year | $4.20 | N/A |
| Revenue Next Year | $3.46 | N/A |
| P/E Ratio | $25.66 | ★ $10.11 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.09 | $2.58 |
| 52 Week High | $5.65 | $7.68 |
Technical Indicators
Market Signals| Indicator | TII | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 30.32 | 45.55 |
| Support Level | $2.09 | $5.85 |
| Resistance Level | $4.30 | $6.15 |
| Average True Range (ATR) | 0.25 | 0.23 |
| MACD | -0.13 | -0.01 |
| Stochastic Oscillator | 0.30 | 28.27 |
Price Performance
Historical ComparisonAbout TII Titan Mining Corporation
Titan Mining Corp is a Canadian natural resources company. It is engaged in the acquisition, exploration, and development of mineral properties. The company owns an interest in the Empire State Mine in Northern New York State, United States. The Company operates one reportable segment, mineral production and exploration in the United States.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.